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Alzheimer’s disease (AD) is the most common form of dementia and causes a progressive and irreversible neurodegeneration. It is related 
with loss of cholinergic function, which aﬀects memory, learning and behavior [1]. Neurophathologically, AD is characterized by the presence 
of beta-amyloid plaques (A) and neuroﬁbrillary tangles (NFT) [2] and consequent degeneration of the basal forebrain cholinergic neurons 
[3]. The loss of cholinergic neurons leads to the progressive reduction of acetylcholine (ACh) in the brain and resulting cognitive impairment 
in AD [3]. As such, the enzyme acetylcholinesterase (AChE) has been one of the prime targets in search for a treatment for AD, which uses 
reversible inhibitors of AChE, in order to increase levels of acetylcholine (ACh) in the brain [4].
In the present study a small library of quinolinone and indole derivatives was screened for their eeAChE inhibitory activity using the Ellman 
method. Rivastigmine was used as benchmark. The IC50  values ranged from 4 to 320 μM. These were promising results when compared to 
the benchmark; therefore our study will continue in order to determine the toxicity and metabolic stability of these potential inhibitors as well 
as screening them for other enzyme targets involved in AD.
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Transthyretin (TTR) amyloidoses comprise a wide spectrum of acquired and hereditary diseases triggered by extracellular deposition of toxic 
TTR aggregates in various organs. Despite recent advances regarding the elucidation of the molecular mechanisms underlying TTR misfold-
ing and pathogenic self-assembly, there is still no eﬀective therapy for treatment of these fatal disorders. Recently, the “molecular tweezers”, 
CLR01, has been reported to inhibit self-assembly and toxicity of diﬀerent amyloidogenic proteins in vitro, including TTR, by interfering with 
hydrophobic and electrostatic interactions known to play an important role in the aggregation process. In addition, CLR01 showed therapeutic 
eﬀects in animal models of Alzheimer’s disease and Parkinson’s disease. 
Here, we assessed the ability of CLR01 to modulate TTR misfolding and aggregation in cell culture and in an animal model. In cell culture 
assays we found that CLR01 inhibited TTR oligomerization in the conditioned medium and alleviated TTR-induced neurotoxicity by redirecting 
TTR aggregation into the formation of innocuous assemblies. To determine whether CLR01 was eﬀective in vivo, we tested the compound in 
mice expressing TTR V30M, a model of familial amyloidotic polyneuropathy, which recapitulates the main pathological features of the human 
disease. Immunohistochemical and Western blot analyses showed a signiﬁcant decrease in TTR burden in the gastrointestinal tract and the 
peripheral nervous system in mice treated with CLR01, with a concomitant reduction in aggregate-induced endoplasmic reticulum stress 
response, protein oxidation, and apoptosis. 
Taken together, our preclinical data suggest that CLR01 is a promising lead compound for development of innovative, disease-modifying 
therapy for TTR amyloidosis.
